Abstract Adrenomedullin (ADM), a peptide characterized by persistent hypotensive activity, is thought to be involved when the control mechanism of blood pressure is deranged, because its plasma concentration is upregulated in hypertensive patients. The receptor for ADM, a molecular complex consisting of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein 2 (RAMP2), is activated through a unique intracellular transport mechanism. By analyzing the nucleotide sequences of bacterial artificial chromosome (BAC) clones, we have established that the gene encoding CRLR is spread over a genomic distance of 103,145 bases; it contains 15 exons interrupted by 14 introns, including 1 that spans more than 60 kilobases. Exons 1-3 constitute the 5Ј noncoding region; exons 4 through 15 are coding elements, of which exons 8 to 14 encode seven transmembrane domains. Eight novel single-nucleotide polymorphisms (SNPs) and their allelic frequencies in the Japanese population were found by direct sequencing of 32 alleles; two SNPs were in the 5Ј flanking region, one in exon 2, and the other five around intron-exon junctions. Eight haplotypes were constructed using these alleles in our Japanese population sample. The data establish a basis for investigations to detect molecular variants in the ADM receptor that might alter control of blood pressure and confer on individuals a predisposition to essential hypertension.
Introduction
Adrenomedullin (ADM) is a recently identified hypotensive peptide, discovered by monitoring the elevated activity of platelet cyclic adenesine monophosphate (cAMP) in a human pheochromcytoma . ADM is characterized by its strong and persistent hypotensive activity due to dilation of the peripheral vascular bed (Ishiyama et al. 1993; Nuki et al. 1993) . Plasma ADM concentrations increase in patients with hypertension, renal failure, heart failure, essential pulmonary hypertension, myocardial infarction, endotoxin shock, and many other physiological conditions (Ishimitsu et al. 1994; Jougasaki et al. 1995; Kakishita et al. 1999; Kobayashi et al. 1996; Nishio et al. 1997) . ADM was first identified in adrenal medulla, but the concentration of ADM in endothelial cells is 20-to 40-fold higher than that in adrenal glands, and ADM is thought to be secreted mainly by vascular endothelial cells and smooth-muscle cells (Sugo et al. 1994a,b) .
ADM receptor is a complex molecule formed by a Gprotein-coupled-receptor with seven transmembrane domains, called calcitonin-receptor-like receptor (CRLR), and a single transmembrane-domain protein called receptoractivity-modifying protein 2 (RAMP2; McLatchie et al. 1998) . The mechanism for its activation is unique: CRLR is transported from endoplasmic reticulum to the cell membrane by RAMP2, where it is core-glycosylated to become a receptor for ADM.
Human CRLR mRNA was isolated from a human cerebellum cDNA library by Fluhmann et al. (1995) . CRLR consists of 461 amino acids, and the gene encoding this protein lies on band q31-q32 of chromosome 2, between markers D2S2257 and D2S115 and flanked by the tissuefactor pathway inhibitor gene and the integrin alpha V gene.
In the work reported here we cloned the entire CRLR gene and determined its genomic structure. We also identi-fied eight single-nucleotide polymorphisms in the gene and constructed haplotypes by direct sequencing of bacterial artificial chromosomes (BACs) and alleles in a panel of 16 normotensive Japanese individuals.
Materials and methods
Genomic cloning of the cDNA sequence BAC screening was carried out by polymenase chain reaction (PCR), using Human Bacterial Artificial Chromosome DNA Pools Release IV (Research Genetics, Huntsville, AL, USA) (Tsukamoto et al. 1998) . Human-insert DNAs on each BAC plate were amplified with the use of specific primers designed on the basis of the human CRLR cDNA sequence (Genbank accession number U17473) and ExTaq polymerase (Takara Shuzou, Kyoto, Japan). Products (5-µl aliquots) from each reaction were assayed on 1.0% agarose gels to decide BAC numbers. Positive BACs were incubated overnight and plasmids were extracted using the Large-Construct Kit (Qiagen, Hilden, Germany).
BAC DNA was amplified with many sets of CRLRspecific primers by LA-Taq polymerase (Takara Shuzou). All of the amplified human inserts were assayed on 1.5% agarose gels and purified using the Qiagen Gel Extraction Kit; BAC plasmids were purified separately by a phenolchloroform method. Sequences of LA-PCR products were determined using BigDye Terminator Cycle-Sequencing FS (PE Biosystems, Foster City, CA, USA) and the ABI PRISM 377-96 sequencer (Applied Biosystems, Foster City, CA, USA). The results were processed with Sequencher version 3.0 software (Hitachi Sottware, Yokohama, Japan) to construct a genomic sequence (Nakajima et al. 1999 ). Subsequently, primers were designed to sequence along the LA-PCR products. Direct sequencing of purified BAC plasmid was also done; the results were assembled and combined with the results of LA-PCR sequencing (Nakajima et al. 2000) . To determine the transcription-start site, we performed 5Ј RACE (rapid amplification of cDNA ends) experiments, using cDNAs from human heart, kidney, lung, and liver, and the SMART RACE cDNA Amplification Kit (Clontech, Palo Alto, CA, USA). The CRLR gene sequence was numbered according to the results of 5Ј RACE. To confirm the 3Ј untranslated region (UTR) sequence and the length of exon 15, 3Ј RACE was done in the same way, using human heart cDNA (Kitamura et al. 1999 ).
Polymorphism analysis and construction of haplotypes
Blood samples from 16 Japanese volunteers were drawn into heparinized tubes, and genomic DNA was extracted by standard techniques as described previously ). All subjects gave their written informed consent to participate in the study and to supply blood samples for DNA analysis. PCR primers were designed on the basis of the CRLR sequence to amplify 15 fragments, including all 15 exons and 2kb of the 5Ј flanking region. A 2-µl sample of each product was assayed on a 1.0% agarose gel to confirm products and the rest were purified using Multiscreen FB (Millipore, Bedford, MA, USA). Direct sequencing was carried out as described previously (Seki et al. 2000) and sequences were compared by Sequencher version 3.0 to detect polymorphisms, which were confirmed by sequencing with reverse primers. Haplotypes were constructed by means of Arlequin software for population genetics data analysis (Genetics and Biometry Laboratory, Geneva, Switzerland).
Results
A human genomic segment, approximately 200-kb long, containing the entire CRLR gene, was cloned as a single contig consisting of overlapping clones of BACs. Nucle- is a strong and long-acting hypotensive peptide, thought to affect hypertension and the physiology of other circulatory diseases. Accordingly, one would expect that the degree of expression of the CRLR gene and the receptor activity of its product would affect the occurrence or development of such conditions. In the study reported here, we investigated the human CRLR gene, to determine its structure and to search for SNPs, in a panel of normotensive human volunteers. The gene consists of 15 exons interrupted by 14 introns, and spans more than 103 kb of genomic DNA. Its transcription start-site, as determined by 5Ј RACE experiments, was in the same position as the 5Ј end of an mRNA reported elsewhere as human CGRP type 1 receptor (Aiyar et al. 1996) .
By direct sequencing of genomic DNAs from 16 Japanese subjects, we detected eight SNPs in the CRLR gene. SNPs in coding sequences of receptor genes can Breathnach and Chambon (1981) ; K, A/G; M, A/C; n, A/C/G/T/; r, A/G; y, C/T b Consensus polyadenylation signal in exon 15 is underlined (Table 1 ). All of the exon-intron boundaries conformed to the GT-AG rule. The introns ranged in size from 82 to 15.4 kb, except for the giant first intron, which spanned 60.3 kb. The translation-start codon was located in exon 4, and a stop codon was present in exon 15. A putative cleavage site for a secretory signal sequence was encoded by exon 5, and three potential post-translation glycosylation sites were encoded by exons 6 and 7. The seven transmembrane domains were encoded by exons 8-15. The results of 5Ј RACE experiments using human heart cDNA indicated a transcription-start site 63,657 bp upstream of the translation-start site. By direct sequencing, we examined 2 kb of the 5Ј flanking region and 5 kb of exonic sequence (15 exons) including exon-intron boundaries, to detect single-nucleotide polymorphisms (SNPs) in 32 alleles from 16 Japanese individuals. Eight novel SNPs were identified in the CRLR gene, two in the 5Ј flanking region, one in exon 2 (5Ј UTR), and five in exon-intron boundaries; details of these alleles and their frequencies are shown in Table 2 . Haplotypes were constructed by means of Arlequin software for population genetic data analysis, using predictions from the genotypes and allele frequencies in the 16 Japanese subjects (Table 3) .
Discussion
CRLR is a unique receptor molecule; it is an ADM receptor when united with RAMP2, and a calcitonin gene-related peptide (CGRP) receptor when united with RAMP1. ADM 
change the structure and ligand-binding activity of receptor molecules by altering amino acid sequences (Bond et al. 1998) . We found no polymorphisms with amino acid replacements in the eight SNPs identified in this study. However, even SNPs in noncoding sequences can affect phenotype (Miller et al. 1999 ), e.g., by altering transcriptional regulation, especially when the polymorphic site lies in a promoter region, or by altering a splice site or latent splice site (Cooper et al. 1995) . Moreover, SNPs are useful in themselves as polymorphic markers for locating mutations associated with specific diseases. Adrenomedullin is thought to play an important functional role in regulating the circulatory system, and abnormal levels of this protein are implicated in the pathogenesis of hypertension. We infer that genetic variations of its receptor, CRLR, may influence susceptibility to this common disease. Additional studies, including a search for more SNPs throughout the CRLR gene, and investigations of DNA from hypertensive patients, may uncover mutations that are responsible for hypertension.
